Treatment Patterns and Preferences for Graves’ Disease in Korea: Insights from a Nationwide Cohort Study
- Author:
Kyeong Jin KIM
1
;
Jimi CHOI
;
Soo Myoung SHIN
;
Jung A KIM
;
Kyoung Jin KIM
;
Sin Gon KIM
Author Information
- Publication Type:Brief Report
- From:Endocrinology and Metabolism 2024;39(4):659-663
- CountryRepublic of Korea
- Language:English
- Abstract: Treatment patterns and preferences for patients with Graves’ disease (GD) vary across countries. In this study, we assessed the initial therapies and subsequent treatment modalities employed for GD in real-world clinical practice in Korea. We analyzed 452,001 patients with GD from 2004 to 2020, obtained from the Korean National Health Insurance Service database. Initial treatments included antithyroid drug (ATD) therapy (98% of cases), thyroidectomy (1.3%), and radioactive iodine (RAI) therapy (0.7%). The rates of initial treatment failure were 58.5% for ATDs, 21.3% for RAI, and 2.1% for thyroidectomy. Even among cases of ATD treatment failure or recurrence, the rates of RAI therapy remained low. Regarding initial treatment, the 5-year remission rate was 46.8% among patients administered ATDs versus 91.0% among recipients of RAI therapy; at 10 years, these rates were 59.2% and 94.0%, respectively. Our findings highlight a marked disparity in the use of RAI therapy in Korea compared to Western countries. Further research is required to understand the reasons for these differences in treatment patterns.
